Physician profile
Austin Tan Hoang
NPI 1851044184
$5,911.30
in general payments reported to CMS, 2019-2025
31 companies · $345 in 2025
The $345 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,529 · 2023: $1,768 · 2024: $1,269 · 2025: $345.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,662 · Travel and Lodging: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,661.62 |
| Travel and Lodging | $720.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,880.29 | 2022-2025 | Synchromedii |
| Relievant Medsystems, INC. | $1,115.23 | 2023 | Intracept |
| Boston Scientific Corporation | $479.58 | 2022-2024 | Wavewriter Alpha Prime 16 |
| Abbvie INC. | $300.84 | 2023-2025 | |
| Si-Bone, INC. | $295.33 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $221.36 | 2023-2024 | Austedo Xr, Ajovy |
| Nevro Corp. | $209.49 | 2022-2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $197.29 | 2024 | Rexulti, Abilify Mycite, Abilify Asimtufii |
| Abbott Laboratories | $141.97 | 2025 | Proclaim, Infinity |
| Lundbeck LLC | $106.80 | 2024 | Rexulti |
| Pfizer INC. | $100.24 | 2025 | |
| Janssen Pharmaceuticals, INC | $89.28 | 2024 | Spravato |
| Spr Therapeutics, INC | $81.43 | 2023 | Sprint Pns System |
| Axsome Therapeutics, INC. | $79.80 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.32 | 2024 | Caplyta |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $55.57 | 2024 | Aristada, Lybalvi |
| Biotronik Nro, INC. | $51.66 | 2023-2024 | Biotronik, Prospera |
| Collegium Pharmaceutical, INC. | $50.24 | 2023 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $46.16 | 2023-2024 | Ztlido |
| Noven Therapeutics, LLC | $43.81 | 2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $38.15 | 2024 | Relexxii |
| Bausch Health US, LLC | $36.91 | 2024 | Aplenzin |
| Neos Therapeutics, Lp | $36.78 | 2024-2025 | Adzenys Xr-Odt |
| Pacira Pharmaceuticals Incorporated | $36.14 | 2023 | Iovera, Zilretta |
| Corium, LLC | $32.41 | 2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $31.97 | 2024 | Qelbree |
| Neurocrine Biosciences, INC. | $23.46 | 2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $19.69 | 2024 | Quviviq |
| Ibsa Pharma INC. | $17.26 | 2023 | Tirosint, Licart |
| Takeda Pharmaceuticals U.S.A., INC. | $17.15 | 2024 | Trintellix |
| Grt US Holding, INC. | $15.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Hoang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.